New Drug Combo Boosts Tirzepatide Weight Loss by 4.5% While Targeting Brain and Muscle Health

Obesity medicine is entering a new phase. While GLP-1 and GIP receptor agonists like tirzepatide have transformed weight loss by suppressing appetite, researchers are now asking whether targeting energy expenditure — not just intake — could unlock even greater benefits. OrsoBio is betting the answer is yes.

At the 2025 American Diabetes Association Scientific Sessions, OrsoBio presented Phase 2a results for TLC-6740, a mitochondrial protonophore designed to increase calorie burning at the cellular level. In a 24-week trial involving adults with obesity but without diabetes, participants who took TLC-6740 alongside tirzepatide lost an additional 4.5% body weight compared to tirzepatide alone. They also showed improvements in insulin sensitivity, liver health, and body composition — outcomes that matter well beyond the number on the scale.

Critically, the combination appeared safe. No severe adverse events, no treatment discontinuations, and no signs of dangerous systemic overactivity were reported. Adverse events were comparable to those typically seen with incretin therapies alone, a meaningful result given historical concerns about compounds that artificially increase metabolic rate.

The broader picture may be even more compelling. Preclinical data on TLC-1180, OrsoBio's next-generation candidate, showed improvements across multiple metabolic tissues — liver, skeletal muscle, heart, and fat. Treated animals ran farther and faster while preserving lean mass. Perhaps most surprisingly, TLC-1180 partially restored memory and exploratory behavior in obese mice with metabolic dysfunction, alongside measurable improvements in neuronal activity in cognition-linked brain regions.

These findings remain early. Animal results frequently fail to replicate in humans, and Phase 2a trials are too small to draw definitive conclusions. Still, the data signal a shift in how obesity treatment — and metabolic aging more broadly — might be approached: not as a single-target problem, but as a multi-pathway opportunity with implications for muscle, brain, and longevity.